Early detection of Alzheimer's disease with PET imaging
Neurodegenerative Diseases, 2010•karger.com
Preclinical diagnosis of Alzheimer's disease (AD) is one of the major challenges for the
prevention of AD. AD biomarkers are needed not only to reveal preclinical pathologic
changes, but also to monitor progression and therapeutics. PET neuroimaging can reliably
assess aspects of the molecular biology and neuropathology of AD. The aim of this article is
to review the use of FDG-PET and amyloid PET imaging in the early detection of AD.
prevention of AD. AD biomarkers are needed not only to reveal preclinical pathologic
changes, but also to monitor progression and therapeutics. PET neuroimaging can reliably
assess aspects of the molecular biology and neuropathology of AD. The aim of this article is
to review the use of FDG-PET and amyloid PET imaging in the early detection of AD.
Abstract
Preclinical diagnosis of Alzheimer’s disease (AD) is one of the major challenges for the prevention of AD. AD biomarkers are needed not only to reveal preclinical pathologic changes, but also to monitor progression and therapeutics. PET neuroimaging can reliably assess aspects of the molecular biology and neuropathology of AD. The aim of this article is to review the use of FDG-PET and amyloid PET imaging in the early detection of AD.
Karger以上显示的是最相近的搜索结果。 查看全部搜索结果